Hi-Affi™ In Vitro Cell based Bradykinin Receptor Functional Assay Service
Bradykinin Receptors with Prospect
Bradykinin receptors are a family of GPCRs and have two subtypes: B1R and B2R, mediating bradykinin signaling. Both are predominantly associated with phospholipase C activation and mediate the vascular aspects of inflammation. Clinical research shows that most efforts to synthesize potent bradykinin antagonists have focused on targeting the B2 bradykinin receptor. The search for B1R antagonists is also crucial because B1Rs are promising candidates for therapeutic development in pain processes. Consequently, identifying the function of bradykinin receptors will broaden their applications in drug development.
Fig.1 Bradykinin B2 receptor contributes to inflammatory responses in human endothelial cells.1
Our Hi-Affi™ In Vitro Cell-based Bradykinin Receptor Functional Assay Service
Hi-Affi™ in vitro cell-based bradykinin receptor functional assay service from Creative Biolabs is carried out via measuring the calcium flux in response to cellular response triggered by the reaction of bradykinin receptors with their ligands. We provide a fast and effective Hi-Affi™ in vitro cell-based bradykinin receptor functional assay service covering from sample treatment to data visualization to meet global customers' diverse needs. Together with our seasoned and expert research teams, we are confident in presenting desirable results for every customer.
Process Diagram
Creative Biolabs has established a powerful technology platform and a strict standard operating procedures to provide global customers with reliable functional assay services. Here is a simplified workflow of our Hi-Affi™ in vitro cell-based bradykinin receptor functional assay service.
Our Highlights
| Cell Bank System | Our stable expressing cell lines include human leukemia Jurkat T cells, human melanoma A375 cell lines, MCF-7 human breast cancer cells, CHO cell lines, etc., making them available for use in a wide variety of research projects by customers throughout the world. |
| Dependable Experiment Platforms | With years of project experience and ongoing optimization, our experimental system is at the cutting edge of today's technology. We are certain that by combining this with straightforward experimental methods, we will be able to provide the desired outcomes for customers all around the world. |
| Professional Research Group | The research team comprises a cohort of specialists possessing substantial professional education, hands-on experience, and specialized knowledge. By leveraging cutting-edge technologies in conjunction with this staff, we are able to deliver data of exceptional quality to clients worldwide. |
| All-Inclusive Customized Support | From experiment design to data presentation, we offer a one-stop customized Hi-Affi™ in vitro cell-based bradykinin receptor functional assay service incorporating the most advanced technological solutions. |
Work with Creative Biolabs
For more details about our Hi-Affi™ in vitro cell-based bradykinin receptor functional assay service, please feel free to get in touch with us. We will be pleased to receive your inquiry. Sincerely look forward to cooperating with global customers.
Frequently Asked Questions
Q1: What are the differences between bradykinin receptors B1 and B2?
A1: The bradykinin receptor has two isoforms: bradykinin type 1 and 2 receptors (B1R and B2R, respectively). B1R expression is modest in naive conditions and increases after inflammation. B2R, on the other hand, is constitutively expressed and does not vary in presentation in response to inflammation. Evidence shows that B2 receptors have a role in more traditional acute inflammatory events including edema and inflammatory pain. In contrast, B1 receptors seem to be engaged in chronic inflammatory responses like persistent hyperalgesia.
Reference
-
Terzuoli, Erika, et al. "Bradykinin B2 receptor contributes to inflammatory responses in human endothelial cells by the transactivation of the fibroblast growth factor receptor FGFR-1." International Journal of Molecular Sciences 19.9 (2018): 2638.
Distributed under Open Access License CC BY 4.0, without modification.
For Research Use Only.